Abstract:Structural classification and regulatory functions of histone deacetylases and their inhibitors. Epigenetic regulation of genes through posttranslational regulation of proteins is a well‐explored approach for disease treatment, particularly in cancer chemotherapy. Histone deacetylases have shown significant potential as effective drug targets in therapeutic studies aiming to restore epigenetic normality in oncology. Besides their role in modifying histones, histone deacetylases can also catalyze the deacetylation of various nonhistone proteins and participate in the regulation of multiple biological processes. This paper provides a review of the classification, structure, and functional characteristics of the four classes of human histone deacetylases. The increasing abundance of structural information on HDACs has led to the gradual elucidation of structural differences among subgroups and subtypes. This has provided a reasonable explanation for the selectivity of certain HDAC inhibitors. Currently, the US FDA has approved a total of six HDAC inhibitors for marketing, primarily for the treatment of various hematological tumors and a few solid tumors. These inhibitors all have a common pharmacodynamic moiety consisting of three parts: CAP, ZBG, and Linker. In this paper, the structure–effect relationship of HDAC inhibitors is explored by classifying the six HDAC inhibitors into three main groups: isohydroxamic acids, benzamides, and cyclic peptides, based on the type of inhibitor ZBG. However, there are still many questions that need to be answered in this field. In this paper, the structure‐functional characteristics of HDACs and the structural information of the pharmacophore model and enzyme active region of HDAC is are considered, which can help to understand the inhibition mechanism of the compounds as well as the rational design of HDACs. This paper integrates the structural‐functional characteristics of HDACs as well as the pharmacophore model of HDAC is and the structural information of the enzymatic active region, which not only contributes to the understanding of the inhibition mechanism of the compounds, but also provides a basis for the rational design of HDAC inhibitors.

Targeting histone deacetylases for heart diseases

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

Targeting histone deacetylase in cardiac diseases

Inhibition of Histone Deacetylases Prevents Cardiac Remodeling After Myocardial Infarction by Restoring Autophagosome Processing in Cardiac Fibroblasts.

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Targeting histone deacetylases for cancer therapy: Trends and challenges

Role of histone deacetylases and their inhibitors in neurological diseases

Advances in the Application of Histone Deacetylase Inhibitors in Eye Disease

Targeting histone deacetylases: Emerging applications beyond cancer

Histone deacetylases: Regulation of vascular homeostasis via endothelial cells and vascular smooth muscle cells and the role in vascular pathogenesis

Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis.

Therapeutic application of histone deacetylase inhibitors for stroke.

Lysine Acetyltransferases and Lysine Deacetylases As Targets for Cardiovascular Disease

HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

HDAC8 as a target in drug discovery: Function, structure and design

Advances in targeting histone deacetylase for treatment of solid tumors

New Development of HDAC Inhibitors As Anti-Cancer Agents

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors

Discussion on structure classification and regulation function of histone deacetylase and their inhibitor

Recent developments of HDAC inhibitors: Emerging indications and novel molecules